SUN-358 Dual Release Hydrocortisone as a New Treatment for Congenital Adrenal Hyperplasia Due to 21-Hydroxylase Deficiency
Sign Up to like & getrecommendations! Published in 2019 at "Journal of the Endocrine Society"
DOI: 10.1210/js.2019-sun-358
Abstract: Abstract In patients with congenital adrenal hyperplasia (CAH) due to 21-hydroxylase deficiency, long-acting glucocorticoids (GCs) and/or multiple daily dose short-acting GCs are historically suggested to disease management. However, these treatment strategies are generally associated with… read more here.
Keywords: treatment; adrenal hyperplasia; release hydrocortisone; due hydroxylase ... See more keywords
Growth of patients with congenital adrenal hyperplasia due to 21-hydroxylase in infancy, glucocorticoid requirement and the role of mineralocorticoid therapy
Sign Up to like & getrecommendations! Published in 2018 at "Journal of Pediatric Endocrinology and Metabolism"
DOI: 10.1515/jpem-2018-0260
Abstract: Abstract Background The dose of hydrocortisone therapy required to maintain normal growth in infants with congenital adrenal hyperplasia (CAH) due to 21-hydroxylase deficiency is lower than in later childhood. This reflects the presence of excess… read more here.
Keywords: growth; adrenal hyperplasia; due hydroxylase; therapy ... See more keywords